Biosimilar Contract Manufacturing Market Size, Value, and Competitive Overview:
[180 Pages Research Report] The global Biosimilar Contract Manufacturing Market size was valued at USD 5.6 billion in 2023, and the market is projected to reach USD 11.1 billion by the end of 2030, with growth at a CAGR of 10.2% during the forecast report 2023-2030.
The "biosimilar contract manufacturing market" refers to the industry where contract manufacturing organizations (CMOs) manufacture biosimilar products. Biosimilar biologic products are ones that are extremely similar to a permitted reference biologic product and do not exhibit any clinically significant differences in safety, purity, or potency.
With a CAGR of 16.6%, the market for biosimilar contract manufacturing is expected to grow from its projected value of USD 2.2 billion in 2020 to USD 7.6 billion by 2028. Growing consumer demand for biosimilar products, the need for cost-effective manufacturing solutions, and growing patient and healthcare provider awareness of the advantages of biosimilars are the main factors driving the market's growth.
Market segments include product type, services, and geographic regions. The market is divided into segments based on the kind of product, including monoclonal antibodies, recombinant proteins, insulin, growth hormones, and others. The market is divided into segments based on services including analytical development, process development, upstream and downstream development, and cell line development.
The market for contract manufacturing of biosimilars is divided geographically into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. Due to its established regulatory environment, the presence of significant players, and its advantageous reimbursement practices, Europe leads the industry. The Asia-Pacific region, on the other hand, is anticipated to experience considerable growth over the course of the forecast period because of the rising demand for biosimilar goods, the increased public awareness of biosimilars, and the presence of a sizable patient base.
Biosimilar medications are gaining popularity due to their accessibility and capacity to offer efficacy and safety profiles that are comparable to those of their reference biologics. Because businesses prefer to outsource their manufacturing to specialized CMOs, the market for biosimilar contract manufacturing services is expanding.
Technological developments: The development of novel cell lines, analytical methods, and bioprocessing technologies is driving the market for biosimilar contract manufacturing. To enhance their manufacturing capabilities and provide their customers with affordable solutions, CMOs are investing in cutting-edge technologies.
The biosimilar contract manufacturing industry is subject to stringent regulations developed by regulatory bodies including the US FDA and the European Medicines Agency (EMA). CMOs must ensure compliance with the laws and regulations, which are always changing, in order to maintain their licenses and certificates.
Growing competition: The industry for biosimilar contract manufacturing is seeing competition from both long-standing companies and newcomers. Businesses are focusing on expanding the breadth of services they provide, growing their technology, and forging strategic alliances in order to get a competitive edge in the market. Healthcare professionals and patients are becoming more aware of biosimilars, which is driving up demand for biosimilar products and contract manufacturing services. Public institutions and healthcare providers
As per the report, the global Biosimilar Contract Manufacturing Market is segmented into Type, Application, and Regions. The report covers detailed information on market size, Share, Growth, Value, Volume Analysis, Demand analysis, new market entry, competition insights, market drivers, challenges, opportunities, and Restraints. Further, company profile analysis, company revenue, Strategies, Sales, company acquisition, partnership, mergers, latest trends in the industry, regional and country-level insights, and competitive intelligence data is provided in the research report.
Further, the global market is geographically divided into major regions, and countries including North America, Europe, Asia Pacific, Middle East and Africa, and Latin America. Further, major countries focused in the global study report: United States, Canada, United Kingdom, Spain, Germany, Italy, France, Mexico, Russia, Ukraine, China, Japan, South Korea, India, Singapore, Malaysia, Australia, Qatar, Kingdom of Saudi Arabia, South Africa, Brazil, Argentina, and other countries are covered in the research study.
by Product
• Recombinant Non-glycosylated Proteins
• Recombinant Glycosylated Proteins
by Production Technology
• Mammalian
• Non-Mammalian
by Application
• Oncology
• Blood Disorders
• Growth Hormonal Deficiency
• Chronic & Autoimmune Disorders
• Rheumatoid Arthritis
• Others
Geographical Classification Analysis:
- North America
- Latin America
- Europe
- Middle East and Africa
- Asia Pacific
Regional Insights:
• North American market to remain in control over the global market during 2022-2030. In the North American region, the United States occupied the highest share of the market in this region, and the US country is projected to follow the same trend over the forecast time 2022-2030, followed by Canada.
• Europe holds the second largest share producer in the global Disposable Medical Sensors Market during the forecast period 2022-2030. Asia Pacific region is expected to be registered as the fastest-growing market in the global market by 2030.
• Most developing countries in Asia Pacific remain the focus of leading Disposable Medical Sensors companies, with a large portion of these companies investing in new entry and business expansion strategies
• The market in the Middle East and Africa is projected to show prominent growth opportunities in the coming years from 2023-2030. Due to the rising focus from the government of the Middle East and African countries on emerging healthcare infrastructure manufacturing and distribution are mostly contributing to the global market in the MEA region.
• The Latin American Disposable Medical Sensors Market registered a substantial share of the global market in 2022, and it is projected to remain its presence in the market.
• Boehringer Ingelheim GmbH
• Lonza Group
• Catalent Inc.
• Biocon Limited
• IQVIA Inc.
• AGC Biologics Inc.
• Samsung Biologics
• WuXi Biologics
• Element Materials Technology Group Limited
• Fujifilm Holdings Corporation
• Thermo Fisher Scientific Corp
• Almac Group
*List not exhaustive
1. Executive Summary
1.1 Introduction to Biosimilar Contract Manufacturing Markets
1.2 Biosimilar Contract Manufacturing Market Size Outlook, 2021- 2030
1.3 Growth Opportunities in Biosimilar Contract Manufacturing Industry
1.4 Winning Strategies for the post-pandemic future
2. Report Guide
2.1 Market Definition and Scope
2.2 Market Segmentation
2.3 Research Methodology
2.4 Forecast Methodology
2.5 List of Abbreviations
3. Growth Opportunity Analysis
3.1 Key Biosimilar Contract Manufacturing Market Trends
3.2 Key Biosimilar Contract Manufacturing Market Growth Drivers
3.3 Key Biosimilar Contract Manufacturing Market Growth Restraints
4 Biosimilar Contract Manufacturing Market Outlook – Scenario Analysis
4.1 Low Growth Case Scenario Forecasts
4.2 Reference Growth Case Scenario Forecasts
4.3 High Growth Case Scenario Forecasts
5. Biosimilar Contract Manufacturing Market Segmentation- Outlook by Product
5.1 Recombinant Non-glycosylated Proteins Market Outlook to 2030
5.2 Recombinant Glycosylated Proteins Market Outlook to 2030
6. Biosimilar Contract Manufacturing Market Segmentation- Outlook by Production Technology
6.1 Mammalian Market Outlook to 2030
6.2 Non-Mammalian Market Outlook to 2030
7. Biosimilar Contract Manufacturing Market Segmentation- Outlook by Application
7.1 Oncology Market Outlook to 2030
7.2 Blood Disorders Market Outlook to 2030
7.3 Growth Hormonal Deficiency Market Outlook to 2030
7.4 Chronic & Autoimmune Disorders Market Outlook to 2030
7.5 Rheumatoid Arthritis Market Outlook to 2030
7.6 Others Market Outlook to 2030
8. North America Biosimilar Contract Manufacturing Market Outlook and Opportunities to 2030
8.1 Market Snapshot, 2023
8.2 North America Biosimilar Contract Manufacturing Market Growth Opportunities
8.3 North America Biosimilar Contract Manufacturing Market Outlook by Application
8.4 North America Biosimilar Contract Manufacturing Market Outlook by Type
8.5 North America Biosimilar Contract Manufacturing Market Outlook by Country
8.6 United States Biosimilar Contract Manufacturing Market Outlook
8.7 Canada Biosimilar Contract Manufacturing Market Outlook
8.8 Mexico Biosimilar Contract Manufacturing Market Outlook
9. Europe Biosimilar Contract Manufacturing Market Outlook and Opportunities to 2030
9.1 Market Snapshot, 2023
9.2 Europe Biosimilar Contract Manufacturing Market Outlook by Application
9.3 Europe Biosimilar Contract Manufacturing Market Outlook by Type
9.4 Europe Biosimilar Contract Manufacturing Market Outlook by Country
9.5 Germany Biosimilar Contract Manufacturing Market Outlook
9.6 France Biosimilar Contract Manufacturing Market Outlook
9.7 United Kingdom Biosimilar Contract Manufacturing Market Outlook
9.8 Spain Biosimilar Contract Manufacturing Market Outlook
9.9 Italy Biosimilar Contract Manufacturing Market Outlook
9.10 Other Europe Biosimilar Contract Manufacturing Market Outlook
10. Asia Pacific Biosimilar Contract Manufacturing Market Outlook and Opportunities to 2030
10.1 Market Snapshot, 2023
10.2 Asia Pacific Biosimilar Contract Manufacturing Market Outlook by Application
10.3 Asia Pacific Biosimilar Contract Manufacturing Market Outlook by Type
10.4 Asia Pacific Biosimilar Contract Manufacturing Market Outlook by Country
10.5 China Biosimilar Contract Manufacturing Market Outlook
10.6 Japan Biosimilar Contract Manufacturing Market Outlook
10.7 India Biosimilar Contract Manufacturing Market Outlook
10.8 Other Asia Pacific Biosimilar Contract Manufacturing Market Outlook
11. Latin America Biosimilar Contract Manufacturing Market Outlook and Opportunities to 2030
11.1 Market Snapshot, 2023
11.2 Latin America Biosimilar Contract Manufacturing Market Outlook by Application
11.3 Latin America Biosimilar Contract Manufacturing Market Outlook by Type
11.4 Latin America Biosimilar Contract Manufacturing Market Outlook by Country
11.5 Brazil Biosimilar Contract Manufacturing Market Outlook
11.6 Argentina Biosimilar Contract Manufacturing Market Outlook
11.7 Other Latin America Biosimilar Contract Manufacturing Market Outlook
12. Middle East and Africa Biosimilar Contract Manufacturing Market Outlook and Opportunities to 2030
12.1 Market Snapshot, 2023
12.2 Middle East and AfricaBiosimilar Contract Manufacturing Market Outlook by Application
12.3 Middle East and AfricaBiosimilar Contract Manufacturing Market Outlook by Type
12.4 Middle East and AfricaBiosimilar Contract Manufacturing Market Outlook by Country
12.5 Saudi Arabia Biosimilar Contract Manufacturing Market Outlook
12.6 UAE Biosimilar Contract Manufacturing Market Outlook
12.7 South Africa Biosimilar Contract Manufacturing Market Outlook
12.8 Other Middle East and Africa Biosimilar Contract Manufacturing Market Outlook
13 Profiles of major Biosimilar Contract Manufacturing Companies
Boehringer Ingelheim GmbH
- Key Statistics
- Business Operations
- Products and Services Offered
- SWOT Analysis
- Financial Analysis
Lonza Group
- Key Statistics
- Business Operations
- Products and Services Offered
- SWOT Analysis
- Financial Analysis
Catalent Inc.
- Key Statistics
- Business Operations
- Products and Services Offered
- SWOT Analysis
- Financial Analysis
Biocon Limited
- Key Statistics
- Business Operations
- Products and Services Offered
- SWOT Analysis
- Financial Analysis
IQVIA Inc.
- Key Statistics
- Business Operations
- Products and Services Offered
- SWOT Analysis
- Financial Analysis
AGC Biologics Inc.
- Key Statistics
- Business Operations
- Products and Services Offered
- SWOT Analysis
- Financial Analysis
Samsung Biologics
- Key Statistics
- Business Operations
- Products and Services Offered
- SWOT Analysis
- Financial Analysis
WuXi Biologics
- Key Statistics
- Business Operations
- Products and Services Offered
- SWOT Analysis
- Financial Analysis
Element Materials Technology Group Limited
- Key Statistics
- Business Operations
- Products and Services Offered
- SWOT Analysis
- Financial Analysis
Fujifilm Holdings Corporation
- Key Statistics
- Business Operations
- Products and Services Offered
- SWOT Analysis
- Financial Analysis
Thermo Fisher Scientific Corp
- Key Statistics
- Business Operations
- Products and Services Offered
- SWOT Analysis
- Financial Analysis
Almac Group
- Key Statistics
- Business Operations
- Products and Services Offered
- SWOT Analysis
- Financial Analysis
14. Appendix
14.1 Publisher’s Expertise
14.2 List of Tables and Charts
14.3 List of Exhibits
14.4 Legal Disclaimer
by Product
• Recombinant Non-glycosylated Proteins
• Recombinant Glycosylated Proteins
by Production Technology
• Mammalian
• Non-Mammalian
by Application
• Oncology
• Blood Disorders
• Growth Hormonal Deficiency
• Chronic & Autoimmune Disorders
• Rheumatoid Arthritis
• Others